❌

Normal view

Boom in weight-loss drugs could lead to fall in beer sales, Heineken warns UK pubs

23 October 2026 at 11:33

World’s second largest brewer says use of drugs such as Wegovy can reduce desire to drink alcohol

• Business live – latest updates

Heineken has warned British bars and pubs that the boom in popularity of weight-loss drugs could lead to a fall in sales of beer and cider.

The world’s second-largest brewer sent a presentation to British hospitality customers earlier this month that said the use of GLP-1 medication – such as Ozempic and Wegovy – could reduce the desire to drink alcohol. This in turn could result in “fullness and fewer serves” of pints in pubs and bars, it added.

Continue reading...

© Photograph: william87/Getty Images/iStockphoto

© Photograph: william87/Getty Images/iStockphoto

© Photograph: william87/Getty Images/iStockphoto

India slashes cost of cancer drugs after court rules mark-ups are ‘extortion’

Case filed in 2022 by patient unable to afford medicine leads to cap on drug prices for millions who face ruin if diagnosed

The Indian government has moved to reduce the price of cancer drugs after a retired bank clerk took her case to the supreme court.

From next month, 137 cancer drugs in India will be cheaper as the government tries to tackle the tragedy of poorer patients either forgoing treatment, selling land or falling into debt to meet the high cost of some medicines, which are making large profits for hospitals and pharmacists.

Continue reading...

© Photograph: Rupendra Rawat/Alamy

© Photograph: Rupendra Rawat/Alamy

© Photograph: Rupendra Rawat/Alamy

Big pharma accused of ‘free-riding on nature’ as global fund attracts just $7,000

22 October 2026 at 10:00

The Cali Fund, set up to raise $1bn a year for biodiversity from drug companies, remains near empty

Big pharmaceutical companies have been accused of “free-riding on nature”, after a landmark biodiversity fund that invites businesses to put some of their profits back into conservation was left virtually empty.

The Cali Fund set out to raise $1bn (£750m) annually, by asking companies that profit from nature’s genetics to contribute towards conservation in low-income countries. But more than 18 months after the fund was launched, it remains far below this target.

Continue reading...

© Photograph: Rebecca Cole/The Guardian

© Photograph: Rebecca Cole/The Guardian

© Photograph: Rebecca Cole/The Guardian

❌